Last update Dec. 2, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Proglumide belongs to this group or family:
Main tradenames from several countries containing Proglumide in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a cholecystokinin antagonist with an inhibitory effect on gastric secretion. Oral, intramuscular or intravenous administration in the treatment of peptic ulcer and other gastrointestinal disorders.
At the date of the last update we did not find any published data on its excretion in breast milk.
The absence of known pharmacokinetic data does not allow the prediction of its possible excretion in breast milk.
Cholecystocinin has been found in the brain and related to development of maternal behaviour in mammals.
Product with very few and/or very old bibliographic references, marketed in few countries.
Safer known alternatives are preferable during breastfeeding, especially during the neonatal period and in case of prematurity.